[Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].
Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18 patients (81.8%) achieved clinical response, and 13 patients (59.1%) were in remission at the 6th week of the observation period. The evaluation was based on data of 22 children. Fistula closure rate was 70% at the at the 6th week. Two patients had acute infusion reaction, one had severe anaphilactic reaction after infliximab infusion. Chronic side effects were also observed in three cases. In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease.
Veres
Gábor
G
Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Gyermekgyógyászati Klinika, Budapest, Bókay J. u. 53., 1083. vergab@gyerl.sote.hu
Szabó
Dolóresz
D
Várkonyi
Agnes
A
Tari
Beáta
B
Polgár
Marianne
M
B Kovács
Judit
J
Horváth
Agnes
A
Tomsits
Erika
E
Tokodi
István
I
Bodánszky
Hedvig
H
Dezsofi
Antal
A
Szakos
Erzsébet
E
Vass
Noémi
N
Ruszinkó
Viktória
V
Kovács
Márta
M
Müller
Katalin Eszter
KE
Arató
András
A
D000203:Activities of Daily Living; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006814:Hungary; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab